Xcelom has been exclusive licensed by CUHK to provide an Non-Invasive Prenatal Technology (NIPT) service called "safeT21express". 

safeT21express is a test that analyses such circulating cell-free DNA molecules with next-generation DNA sequencing technologies, and performs bioinformatics analysis. Genetic information from the unborn child can be obtained, which could include the screening results for:
-	Down syndrome (T21)
-	Edwards syndrome (T18)
-	Patau syndrome (T13)
-	Sex chromosome aneuploidies: 45, X0 (Turner syndrome)
-	Sex chromosome aneuploidies: 47, XXY (Klinefelter syndrome)
-	Sex chromosome aneuploidies: 47, XXX (Triple X)
-	Sex chromosome aneuploidies: 47, XYY (Jacob syndrome)
-	Microdeletions analysis related to 1p36 deletion syndrome
-	Microdeletions analysis related to 2q33.1 deletion syndrome
-	Microdeletions analysis related to Angelman syndrome
-	Microdeletions analysis related to Cri-du-Chat syndrome
-	Microdeletions analysis related to 22q11 deletion syndrome (include DiGeorge syndrome)
-	Microdeletions analysis related to Langer-Giedion syndrome
-	Microdeletions analysis related to Prader-Willi syndrome

Looking ahead, Xcelom will continue to use Hong Kong as its base to market its NIPT solution to Asia and the rest of the world.

Xcelom Limited

Org chart

Teams

Offices